O’Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S. 1985. Effects of anthrax toxin components on human neutrophils. Infection and Immunity 47(1):306–310.


Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C. 1999. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN?-induced release of NO and TNFa. FEBS Letters 462(1–2):199–204.

Pittman PR, Kim-Ahn G, Pifat DY, Coon K, Gibbs P, Little S, Pace-Templeton J, Myers R, Parker GW, Friedlander AM. 2002. Anthrax vaccine: safety and immunogenicity of a dose-reduction, route comparison study in humans. Vaccine 20(9–10):1412–1420.

Puziss M, Wright GG. 1963. Studies on immunity in anthrax. X. Gel adsorbed protective antigen for immunization of man. Journal of Bacteriology 85:230–236.


Rosenthal S, Chen R. 1995. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. American Journal of Public Health 85(12):1706–1709.

Rovet RJ, Lieutenant, U.S. Air Force. 1999. Anthrax Vaccine Adverse Event Reporting. Statement at the July 21, 1999 hearing of the Subcommittee on National Security, Veterans Affairs and International Relations, Committee on Government Reform, U.S. House of Representatives, Washington, D.C.

Rugo N. 2001. Statement of Nancy Rugo on behalf of Sandy Larson. Institute of Medicine Joint Meeting of the Committee to Assess the Safety and Efficacy of the Anthrax Vaccine and the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, Meeting III , Washington, D.C.


Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. 1999. An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system. VAERS Working Group. Vaccine 17(22):2908–2917.

Starkweather T. 2001. Statement. Institute of Medicine Joint Meeting of the Committee to Assess the Safety and Efficacy of the Anthrax Vaccine and the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, Meeting III, Washington, D.C.


Tilson H. 1992. Pharmacosurveillance: public health monitoring of medication. In: Halperin W, Baker EL, Monson RR (consulting ed.), eds. Public Health Surveillance. New York: Van Nostrand Reinhold. Pp. 206–229.

Turnbull PC. 1991. Anthrax vaccines: past, present and future. Vaccine 9(8):533–539.

Turnbull PCB. 2000. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Current Opinion in Infectious Diseases 13(2):113–120.


VAERS (Vaccine Adverse Event Reporting System). 2001. A federal program for surveillance of vaccine safety. Brochure. Vaccine Adverse Event Reporting System, Rockville, Md.

Vick DF. 2001. Submitted statement. Institute of Medicine Joint Meeting of the Committee to Assess the Safety and Efficacy of the Anthrax Vaccine and the Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, Meeting III , Washington, D.C.


Weiss R. 2001, September 29. Demand growing for anthrax vaccine: fear of bioterrorism attack spurs requests for controversial shot. Washington Post. p. A16.

Wolfowitz P. 2002. Reintroduction of the Anthrax Vaccine Immunization Program (AVIP). Memorandum for Secretaries of the Military Departments; Chairman of the Joint Chiefs of Staff; Under Secretaries of Defense; Assistant Secretaries of Defense; General Counsel, Department of Defense; Inspector General, Department of Defense; Directors of Defense Agencies; and Commandant of the U.S. Coast Guard. Department of Defense, Washington, D.C.

Wright GG, Puziss M. 1957. Elaboration of protective antigen of Bacillus anthracis under anaerobic conditions. Nature 179:916–917.

Wright GG, Green TW, Kanode RG Jr. 1954a. Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen. Journal of Immunology 73:387–391.

Wright GG, Hedberg MA, Slein JB. 1954b. Studies on immunity in anthrax. III. Elaboration of protective antigen in a chemically-defined, non-protein medium. Journal of Immunology 72:263–269.

Wright GG, Puziss M, Neely WB. 1962. Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis. Journal of Immunology 83:515–522.


Zilinskas RA. 1997. Iraq’s biological weapons: the past as future? JAMA 278(5):418–424.

Zoon KC. 1997. Inspections of Michigan Biologic Products Institute, November 18 and 27, 1996. Letter to Myers, R, Michigan Biologic Products Institute, Lansing, Mich.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement